Skip to main content
SpringerLink
Log in

lontophoretic Delivery of Apomorphine I: In Vitro Optimization and Validation

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To investigate the feasibility of transdermal iontophoretic delivery of apomorphine in patients with Parkinson's disease, transdermal transport rates were optimized and validated across human stratum corneum and freshly dermatomed human skin in vitro.

Methods. In all experiments R-apomorphine hydrochloride was applied in the anodal compartment. The effect on the flux of the following parameters was studied, using a flow through transport cell: current density, pH, concentration, ionic strength, osmolarity, buffer strength, temperature and skin type.

Results. Transdermal transport of apomorphine was directly controlled by the presence or absence of current. Passive delivery was minimal and no depot effect was observed. A linear relationship was found between current density and steady-state flux. At room temperature the lag time was 30 to 40 minutes. A maximal steady-state flux was obtained when the donor concentration approached maximum solubility. By increasing the temperature of the acceptor chamber to 37°C, the steady-state flux was increased by a factor of 2.3 and the lag time decreased to ± 3 minutes. No effect of osmolarity and buffer strength, and only a small effect of ionic strength and pH on the transport rate were observed. The flux through dermatomed human skin was decreased compared to stratum corneum. This effect was shown not to be caused by skin metabolism.

Conclusions. The results obtained in vitroindicate that the iontophoretic delivery of apomorphine can be controlled and manipulated accurately by the applied current. The in vitro flux furthermore depends on the donor composition, temperature and skin type. Under optimized conditions, transport rates resulting in therapeutically effective plasma concentrations are feasible, assuming a one to one in vitro/in vivo correlation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. M. Danhof, J. W. Mandema, A. Hoogerkamp, and R. A. Mathôt. Eur. J. Drug Metab. Pharmacokinet. 18:41–47 (1993).

    Google Scholar 

  2. R. J. Hardie, A. J. Lees, and G. M. Stern. Brain 107:487–50 (1984).

    Google Scholar 

  3. T. van Laar, R. van der Geest, M. Danhof, H. E. Boddé, P. H. Goossens, and R. A. C. Roos. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. Clin. Neuropharmacol. (in press).

  4. A. J. Lees. Fundam. Clin. Pharmacol. 7:121–128 (1993).

    Google Scholar 

  5. J. P. Frankel, A. J. Lees, P. A. Kempster, and G. M. Stern. J. Neurol. Neurosurg. Psychiatry 53:96–101 (1990).

    Google Scholar 

  6. S. T. Gancher, J. G. Nutt, and W. R. Woodward. Mov. Disord. 6:212–216 (1991).

    Google Scholar 

  7. F. Durif, E. Beyssac, F. Coudoré, M. Paire, A. Eschalier, M. Aiache, and J. Lavarenne. Clin. Neuropharmacol. 17:445–453 (1994).

    Google Scholar 

  8. B. H. Sage. Iontophoresis. In E. W. Smith and H. I. Maibach (eds.), Percutaneous Penetration Enhancers, CRC Press, Boca Raton, 1995, pp. 351–368.

    Google Scholar 

  9. N. H. Yoshida and M. S. Roberts. Adv. Dr. Del. Rev. 9:239–264 (1992).

    Google Scholar 

  10. P. G. Green. J. Control. Rel. 41:33–48 (1996).

    Google Scholar 

  11. R. van der Geest, M. Danhof, and H. E. Boddé. Validation and testing of a new iontophoretic continuous flow through transport cell. J. Control. Rel. (1997) in press.

  12. T. van Laar, J. J. van Hilten, C. Neef, A. W. F. Rutgers, S. Pavel, and J. A. Bruyn. Allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease are caused by EDTA: A histological study. (submitted).

  13. R. van der Geest, P. Kruger, J. M. Gubbens-Stibbe, T. van Laar T, H. E. Boddé, and M. Danhof. Assay of R-apomorphine, S-apomorphine, apocodeine and isoapocodeine and their glucuronide and sulphate conjugates in plasma and urine of patients with Parkinson's disease. J. Chromatogr. (1997) in press.

  14. P. G. Green, R. S. Hinz, A. Kim, F. C. Szoka, and R. H. Guy. Pharm. Res. 8:1121–1127 (1991).

    Google Scholar 

  15. N. M. Volpato, P. Santi, and P. Colombo. Pharm. Res. 12:1623–1627 (1995).

    Google Scholar 

  16. V. Préat and S. Thysman. Int. J. Pharm. 96:189–196 (1993).

    Google Scholar 

  17. D. F. Hager, M. J. Laubach, J. W. Sharkey, and J. R. J. Control. Rel. 23:175–182 (1993).

    Google Scholar 

  18. R. van der Geest, T. van Laar, P. P. Kruger, J. M. Gubbens-Stibbe, H. E. Boddé, R. A. C. Roos, and M. Danhof. Pharmacokinetics, enantiomer interconversion and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. (submitted)

  19. R. V. Padmanabhan, J. B. Phipps, G. A. Lattin, and R. J. Sawchuk. J. Control. Rel. 11:123–135 (1990).

    Google Scholar 

  20. M. B. Delgado-Charro and R. H. Guy. Pharm. Res. 11:929–935 (1994).

    Google Scholar 

  21. A. J. Hoogstraate, V. Srinivasan, S. M. Sims, and W. I. Higuchi. J. Control. Rel. 31:41–47 (1994).

    Google Scholar 

  22. J. E. Sanderson, S. Riel, and R. Dixon. J. Pharm. Sci. 78:361–364 (1989).

    Google Scholar 

  23. L. Wearley, J-C. Liu, and Y. W. Chien. J. Control. Rel. 8:237–250 (1989).

    Google Scholar 

  24. J. B. Phipps and J. R. Gyory. Adv. Dr. Del. Rev. 9:137–176 (1992).

    Google Scholar 

  25. I. H. Patel and R. H. Levy. J. Pharmacokin. Biopharm. 2:337–346 (1974).

    Google Scholar 

Download references

Author information

Author notes

  1. Ronald van der Geest

    Present address: Department of Clinical Pharmacokinetics, Janssen Pharmaceutics, Beerse, Belgium

Authors and Affiliations

  1. Division of Pharmaceutical Technology, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands

    Ronald van der Geest & Harry E. Boddé

  2. Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands

    Ronald van der Geest & Meindert Danhof

Authors
  1. Ronald van der Geest
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meindert Danhof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harry E. Boddé
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meindert Danhof.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Geest, R., Danhof, M. & Boddé, H.E. lontophoretic Delivery of Apomorphine I: In Vitro Optimization and Validation. Pharm Res 14, 1798–1803 (1997). https://doi.org/10.1023/A:1012100417645

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012100417645

Search

Navigation